

de ERC, el peso o el índice de masa corporal al momento de colocado el catéter, entre otros.

El uso de CTL o CTH son una opción viable y segura para nuestros pacientes, permiten un acceso venoso viable en pacientes con pocas opciones para diálisis mientras esperan un trasplante renal o cambio a diálisis peritoneal.

## Agradecimientos

Al Dr. Juan Vicente Guanira del Instituto de Evaluación de Tecnologías en Salud e Investigación (IETS) - EsSalud.

## BIBLIOGRAFÍA

1. Younes H, Pettigrew C, Anaya-Ayala J, Soltes G, Saad W, Davies M, et al. Transhepatic hemodialysis catheters: Functional outcome and comparison between early and late failure. *J Vasc Interv Radiol.* 2011;22, 183-191.
2. Power A, Singh S, Ashby D, Hamady M, Moser S, Gedroyc W, et al. Translumbar central venous catheters for long-term haemodialysis. *Nephrol Dial Transplant.* 2010;25:1588-95.
3. El Gharib M, Niazi G, Hetta W, Makkeyah Y. Transhepatic venous catheters for hemodialysis. *The Egyptian Journal of Radiology and Nuclear Medicine.* 2014;45:431-8.
4. Smith T, Ryan M, Reddan D. Transhepatic catheter access for hemodialysis. *Radiology.* 2004;232:246-51.
5. Mauricio da Motta, Carnevale F, Nasser F, de Oliveira W, Zurtrassen C, Motta A, et al. Percutaneous transhepatic venous Access for hemodialysis: An alternative route for patients with end-stage renal failure. *J Vasc Bras.* 2010;9. <https://doi.org/10.1590/S1677-54492010000300006>
6. Liu F, Bennett S, Arrigain S, Schold J, Heyka R, McLennan G, et al. Patency and complications of translumbar dialysis catheters. *Seminars in Dialysis.* 2015;28:E41-7.
7. Stavropoulos SW, Pan JJ, Clark TWI, Soulen MC, Shlansky-Golberg RD, Itkin M, Trerotola SO. Percutaneous transhepatic venous access for hemodialysis. *J Vasc Interv Radiol.* 2003;14:1187-90.
8. Lund GB, Lieberman RP, Haire WD, Martin VA, Kessinger A, Armitage JO. Translumbar inferior vena cava catheters for long-term venous access. *Radiology.* 1990;174:31-5.
9. Nadolski G, Trerotola S, Stavropoulos W, Shlansky-Goldberg R, Soulen M, Farrelly C. Translumbar hemodialysis catheters in patients with limited central venous access: Does patient size matter? *J Vasc Interv Radiol.* 2013;24:997-1002.

Juan Rodriguez Mori\*, Jhony Ramirez Alguar, Carla Postigo Oviedo, Piero Mora Munares, Manuel Llaro Sanchez, Max Caballero Linares y Manuel Castillo Zegarra

Unidad de Radiología Intervencionista, Servicio de Nefrología, Hospital Nacional Alberto Sabogal Sologuren, Lima, Perú

\* Autor para correspondencia.

Correos electrónicos: [kiker98@hotmail.com](mailto:kiker98@hotmail.com), [rodriguez Mori.juan@gmail.com](mailto:rodriguez Mori.juan@gmail.com) (J. Rodriguez Mori).

0211-6995/© 2018 Sociedad Española de Nefrología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). <https://doi.org/10.1016/j.nefro.2017.12.004>


# Improvement of bilateral lower-limb muscle oxygenation by low-density lipoprotein apheresis in a patient with peripheral artery disease undergoing hemodialysis

## Mejora de la oxigenación en los músculos de ambos miembros inferiores mediante aféresis de lipoproteínas de baja densidad en un paciente con arteriopatía periférica sometido a diálisis

Dear Editor:

Low-density lipoprotein apheresis (LDL-A), frequently used for peripheral artery disease (PAD) treatment, is expected to induce the improvement of systemic microcirculation.<sup>1</sup> Recently, near-infrared spectroscopy was used to evaluate tissue regional oxygen saturation (rSO<sub>2</sub>) in haemodialysis (HD) patients.<sup>2-5</sup> However, there is no report regarding the relation between LDL-A and changes in tissue oxygenation. In our HD patient, we confirmed an improvement in lower-limb muscle oxygenation during LDL-A.

An 82 year-old woman receiving HD was referred to our hospital for treatment of PAD recurrence. Her past medical history included hypertension and insulin-dependent diabetes. HD was initiated beginning 5-years prior. She was diagnosed with PAD and underwent bypass surgery for the right lower leg 4-years ago. Deteriorations of colour of foot skin and foot ulceration were recently confirmed bilaterally in the lower legs; therefore, LDL-A was performed for preventing PAD progression in our dialysis centre. Blood circuits of each LDL-A and HD were tandemly connected: each therapy was simultaneously performed. LDL-A was performed using Plasmaflo OP (Asahi



**Fig. 1 – The changes in  $rSO_2$  of the forehead and bilateral lower-limb muscle as per the oxygenation values of cerebral and muscle tissues, respectively, under LDL-A with HD.  $rSO_2$  ratio is defined as the ratio of  $rSO_2$  value at  $t$  (min) during HD and initial  $rSO_2$  value before HD ( $rSO_2$  at  $t$  (min) during HD/initial  $rSO_2$  before HD). The open circle represents the changes in cerebral  $rSO_2$  values, the grey diamond shape represents the changes in right lower-limb muscle  $rSO_2$  values, and the block diamond shape represents the changes in left lower-limb muscle  $rSO_2$  values.**

Kasei Medical, Tokyo, Japan) as a plasma separator, a dextran sulfate cellulose column (Liposorba 15, Kaneka, Osaka, Japan) as a LDL absorber, and 1000 U/h of heparin sodium as an anticoagulant. Plasma volume was treated at a rate of 50 mL/kg per LDL-A session. The duration of LDL-A with HD was 4-h: totally, she received LDL-A once a week for 10 consecutive weeks. During these 10 weeks of LDL-A with HD, other sessions of HD therapy twice a week was performed at a dialysis clinic that she had been receiving that therapy. To confirm LDL-A's influence on microcirculation impairment, tissue  $rSO_2$  values in brain and lower-limb muscle were monitored from LDL-A with HD initiation to the end. Written informed consent for  $rSO_2$  monitoring during that therapy was obtained. Values of  $rSO_2$  were monitored at forehead and bilateral lower-limbs above the gastrocnemii using INVOS 5100c (Covidien Japan, Tokyo, Japan) during second, sixth and 10th sessions of LDL-A with HD. Fluid was removed by ultrafiltration at the level of  $1.3 \pm 0.4$  L/session, and haemoglobin levels increased from  $9.9 \pm 0.4$  g/dL before LDL-A with HD to  $11.0 \pm 0.2$  g/dL after therapy. The  $rSO_2$  ratios (mean  $\pm$  standard deviation) in bilateral lower-limb muscles rapidly increased from LDL-A with HD initiation to the end, whereas cerebral  $rSO_2$  ratio did not change during that therapy (Fig. 1). Notably, changes in the colour of the foot skin and foot ulceration status improved by LDL-A with HD for 10 consecutive weeks.

LDL-A has been applied in PAD patients in whom efficacy of conventional pharmacological therapy is insufficient and/or those who are unavailable for surgical therapy because LDL-A itself improves peripheral microcirculation via blood rheology amelioration; reduction of blood and plasma viscosity; production of vasodilating nitric oxide, eicosanoids, and bradykinin; improvement of endothelial function through

reduction of total LDL and oxidized LDL concentrations; and reduction of circulating inflammatory cytokines and chemokines.<sup>6</sup> Improvement of peripheral microcirculation associated with LDL-A would also be expected to improve tissue oxygenation via increased oxygen supply in peripheral tissues. Indeed, oxygen partial pressure ( $pO_2$ ) in the anterior tibial muscle rapidly and significantly increased during LDL-A in cardiac allograft vasculopathy patients.<sup>7</sup> In the present case, bilateral lower-limb muscle oxygenation rapidly improved from LDL-A with HD initiation to the end; our result is consistent with a previous report.<sup>7</sup> Ebihara et al. measured systemic blood flow using a laser doppler blood flowmeter during LDL-A, and reported significant increases in tissue blood flow in the head and lower limbs, in which the increase of blood flow was significantly higher in the lower limbs than in the head.<sup>1</sup> We did not evaluate the level of tissue blood flow during LDL-A with HD in this case; therefore, we cannot comment on LDL-A-induced blood flow changes in systemic tissues. However, regarding cerebral oxygenation, little changed despite the increase in lower-limb muscle oxygenation; these differences in tissue oxygenation in the brain and lower-limb muscle might be explained by differences in blood flow increase in the head and lower-limb muscle previously reported.<sup>1</sup> Additionally, our patient simultaneously received LDL-A and HD therapy; therefore, it could not be definitively determined that the improvement in bilateral lower-limb muscle oxygenation was derived only from the application of LDL-A itself. Regarding tissue oxygenation during HD, there were reportedly no significant changes in cerebral and lower-limb muscle  $rSO_2$  values during HD, respectively, although Hb levels after HD increased compared with those before HD.<sup>2,8</sup> Therefore, the improvement in muscle oxygenation seen in this case might be caused not by HD therapy but by LDL-A itself.

In conclusion, LDL-A may have improved lower-limb muscle oxygenation in our patient. Thus, it might have positive effects for lower-limb muscle microcirculation.

### Conflict of interest statement

The authors have declared that no conflict of interest exists.

### Acknowledgement

We thank the monitored HD patient and dialysis staffs members in our hospital. This work was supported with a grant from the Japanese Association of Dialysis Physicians (No. 27088) provided to S.O., and a grant from The Kidney Foundation, Japan (JKFB16-3) provided to S.O.

### BIBLIOGRAFÍA

1. Ebihara I, Sato T, Hirayama K, Seki M, Enami T, Kawahara H, et al. Blood flow analysis of the head and lower limbs by the laser Doppler blood flowmeter during LDL apheresis. *Ther Apher Dial.* 2007;11:325–30.
2. Hoshino T, Ookawara S, Goto S, Miyazawa H, Ito K, Ueda Y, et al. Evaluation of cerebral oxygenation in patients undergoing long-term hemodialysis. *Nephron Clin Pract.* 2014;126:57–61.

3. Ito K, Ookawara S, Ueda Y, Goto S, Miyazawa H, Yamada H, et al. Factors affecting cerebral oxygenation in hemodialysis patients: cerebral oxygenation associates with pH, hemodialysis duration, serum albumin concentration, and diabetes mellitus. *PLOS ONE*. 2015;10:e0117474.
4. Malik J, Kudlicka J, Lachmanova J, Valerianova A, Rocinova K, Bartkova M, et al. Tissue ischemia worsens during hemodialysis in end-stage renal disease patients. *J Vasc Access*. 2017;18:47-51.
5. Ito K, Ookawara S, Ueda Y, Uchida T, Kofuji M, Hayasaka H, et al. Blood transfusion during haemodialysis improves systemic tissue oxygenation: a case report. *Nefrologia*. 2017;37:435-7.
6. Hirai K, Ookawara S, Miyazawa H, Ito K, Ueda Y, Kaku Y, et al. Low-density lipoprotein apheresis ameliorates monthly estimated glomerular filtration rate declines in patients with renal cholesterol crystal embolism. *J Artif Organs*. 2015;18:72-8.
7. Matschke K, Mrowietz C, Stemitzky R, Jung F, Park JW. Effect of LDL apheresis on oxygen tension in skeletal muscle in patients with cardiac allograft vasculopathy and severe lipid disorder. *Clin Hemorheol Microcirc*. 2004;30:263-71.
8. Ookawara S, Ito K, Ueda Y, Miyazawa H, Hayasaka H, Kofuji M, et al. Differences in tissue oxygenation and changes in total hemoglobin signal strength in the brain, liver, and lower-limb muscle during hemodialysis. *J Artif Organs*. 2017 Aug 7, <http://dx.doi.org/10.1007/210047-017-0978-1>.

Kiyonori Ito<sup>a</sup>, Susumu Ookawara<sup>a,\*</sup>, Yuichiro Ueda<sup>a</sup>, Hideyuki Hayasaka<sup>b</sup>, Masaya Kofuji<sup>b</sup>, Takayuki Uchida<sup>b</sup>, Harunobu Matsumoto<sup>c</sup>, Atsushi Yamaguchi<sup>c</sup>, Yoshiyuki Morishita<sup>a</sup>

<sup>a</sup> Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan

<sup>b</sup> Department of Clinical Engineering, Saitama Medical Center, Jichi Medical University, Saitama, Japan

<sup>c</sup> Department of Cardiovascular Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan

\* Corresponding author.

E-mail address: [su-ooka@hb.tp1.jp](mailto:su-ooka@hb.tp1.jp) (S. Ookawara).

0211-6995/© 2018 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<https://doi.org/10.1016/j.nefro.2017.11.023>

## Prescripción potencialmente inapropiada en pacientes en diálisis utilizando los criterios STOPP-START

### Potentially inappropriate prescribing in patients on dialysis using STOPP-START criteria

Sr. Director:

La prescripción potencialmente inadecuada (PPI) de fármacos es aquella cuyo riesgo de efectos adversos es mayor que el beneficio clínico. También se considera PPI el uso de medicamentos en dosis o duración superior a la óptima, con potenciales interacciones entre sí o con las enfermedades del paciente, así como las duplicidades terapéuticas. Además se considera inadecuada la omisión de medicamentos con indicación establecida.

Una de las herramientas más utilizadas en Europa para la detección de PPI son los criterios Screening Tool of Older Person's inappropriate Prescription (STOPP)/Screening Tool to Alert Doctor to Right Treatment (START) propuestos por Gallagher et al. en 2008<sup>1</sup> y aceptados por la Sociedad Española de Geriatría<sup>2</sup>. Recientemente se han actualizado incorporando nuevos datos, o por la llegada de nuevos fármacos e identificación de medicamentos considerados potencialmente inadecuados<sup>3,4</sup>.

Existe poca información sobre la PPI en pacientes con insuficiencia renal crónica<sup>5-7</sup>. Por ello decidimos realizar un estudio con el objetivo de detectar de forma sistemática, según los criterios STOPP/START, la PPI en los 103 enfermos en

diálisis de nuestro hospital. Para ello se revisaron las historias farmacoterapéuticas de todos estos pacientes recogiendo las siguientes variables (tabla 1): edad, sexo, número de principios activos, número de pastillas, número de médicos prescriptores y criterios STOPP/START identificados.

Se encontró que el 69,9% (72) de los enfermos tenían al menos una prescripción potencialmente inadecuada y se detectaron 231 prescripciones inapropiadas (132 START y 99 STOPP).

Según los criterios STOPP (herramienta para la detección de prescripciones potencialmente inapropiadas) las causas más frecuentes de PPI fueron (tabla 2): A1 (cualquier medicamento prescrito sin una indicación basada en la evidencia); A2 (cualquier medicamento prescrito con una duración superior a la indicada, cuando la duración del tratamiento esté bien definida); D5 (benzodiazepinas durante más de 4 semanas, sin indicación); F2 (inhibidor de la bomba de protones durante más de 8 semanas, sin indicación). Para los criterios START (herramienta para llamar la atención del médico sobre los tratamientos indicados y apropiados): A3 (ausencia de antiagregantes como AAS, clopidogrel, prasugrel o ticagrelor en enfermos con antecedentes bien documentados de enfermedad vascular coronaria, cerebral o periférica); A4 (ausencia